



Regulus Therapeutics Inc.
Investor Relations Department
10614 Science Center Dr
San Diego, CA 92121
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: RGLS

| | |
|---------------|--|
| Last Trade: | 0.98 |
| Trade Time: | 4:00 PM ET Jul 21, 2017 |
| Change: | 0.10 ▲ (+11.364%) |
| Day Range | 0.88 - 0.99 |
| 52-Week Range | 0.86 - 4.25 |
| Volume | 779,148 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting *microRNAs*. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced *microRNA* therapeutics pipeline complemented by a maturing *microMarkers*SM biomarkers platform and a rich intellectual property estate to retain its leadership in the *microRNA* field. Regulus is developing RG-101, a GalNAc-conjugated anti-miR targeting *microRNA*-122 for the tre... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jul 19, 2017 [Regulus Announces Pricing of Public Offering of Common Stock](#)
- Jul 19, 2017 [Regulus Announces Commencement of Public Offering of Common Stock](#)
- Jun 13, 2017 [Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer](#)
- Jun 12, 2017 [Regulus Announces Pipeline Updates and Advancements](#)
- Jun 1, 2017 [Pascale Witz Joins Regulus Board of Directors](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Mar 3, 2017 [Annual Report \(10-K\)](#)
- Apr 28, 2017 [Proxy Statement \(DEF 14A\)](#)
- May 5, 2017 [Quarterly Report \(10-Q\)](#)
- Nov 2, 2016 [Quarterly Report \(10-Q\)](#)
- Aug 3, 2016 [Quarterly Report \(10-Q\)](#)